Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Women Catch Up to Men in Smoking-Related Mortality Risk

February 2, 2013
By Dave Levitan
Article

Women have caught up to men with regard to the risk of death from cigarette smoking, according to analyses of three study cohorts spanning multiple decades and hundreds of thousands of individuals.

Women have caught up to men with regard to the risk of death from cigarette smoking, according to analyses of three study cohorts spanning multiple decades and hundreds of thousands of individuals. The risk of death among men has largely plateaued since the 1980s, though there has been an increase in mortality related to chronic obstructive pulmonary disease (COPD).

The new study’s authors, led by Michael J. Thun, MD, of the American Cancer Society in Atlanta, noted that smoking patterns have changed over several generations, which have altered the associated risks. “Daily cigarette consumption peaked during the 1970s among male smokers and during the 1980s among female smokers; smoking prevalence in the two groups has since decreased in parallel,” they wrote in the January 24 issue of the New England Journal of Medicine. “Women have more difficulty quitting than men; thus, for both current and former female smokers, the number of years of smoking has increased.”

The authors calculated death rates during three time periods: 1959–1965, 1982–1988, and 2000–2010, using two historical Cancer Prevention Study (CPS) cohorts and pooled data from five contemporary cohort studies. The CPS cohorts included 183,060 men and 335,922 women in the earlier study and 293,592 men and 452,893 women in the 1980s cohort. The pooled contemporary analysis involved cohorts ranging in size from about 33,000 men and 75,000 women up to more than 300,000 men and 200,000 women.

The relative risk of death from lung cancer for women who smoked vs those who did not increased across the three time periods, from 2.73, to 12.65, to 25.66 in the most recent period. In contrast, the relative risk for male smokers increased from 12.22 in the earliest period to 23.81 in the 1980s, but stayed relatively stable to the 2000s, when it reached 24.97.

In the modern cohorts, the relative risks of death from COPD were similar for men (25.61) and women (22.35) vs nonsmokers; this was also the case for relative risks of ischemic heart disease (2.5 for men and 2.86 for women), stroke (1.92 for men and 2.1 for women), and all-cause mortality (2.8 for male smokers and 2.76 for female smokers). The relative risk of death from COPD rose sharply among male smokers, from the 1980s period (9.98) to the contemporary period, in contrast to the relatively stable lung cancer mortality risk.

The authors wrote that the similar risks for men and women is a new finding and “confirms the prediction that, in relative terms, ‘women who smoke like men die like men.’” The convergence of risk reflects a convergence of smoking patterns, they noted, and added that quitting smoking by the age of 40 would ensure nearly all excess mortality risk to be avoided.

In an accompanying editorial in the New England Journal of Medicine, Steven A. Schroeder, MD, of the University of California, San Francisco, wrote that cohort studies such as this capture trends “but omit nuances.” Among those omissions is a lack of data on frequency of smoking, an important point since an increasing proportion of smokers are light smokers. The cohorts featured also overrepresented people who were better educated, reflected in lower overall smoking rates than the general population.

“The importance of smoking as a health hazard needs to be elevated,” Schroeder wrote. “More women die of lung cancer than of breast cancer. But there is no ‘race for the cure’ for lung cancer, no brown ribbon…. The need for greater attention to the policies known to reduce the prevalence of smoking remains urgent.”

Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content
Advertisement

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese
June 6th 2025
Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC

Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC

Tim Cortese
June 4th 2025
Article

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

Tim Cortese
June 2nd 2025
Article

Neoadjuvant alectinib met the primary end point with a major pathologic response rate of 42% in patients with potentially resectable stage III NSCLC.


3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.

Related Content
Advertisement

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese
June 6th 2025
Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC

Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC

Tim Cortese
June 4th 2025
Article

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.


Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.


Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

Tim Cortese
June 2nd 2025
Article

Neoadjuvant alectinib met the primary end point with a major pathologic response rate of 42% in patients with potentially resectable stage III NSCLC.


3 Things You Should Know About the Multimodal Treatment of SCLC

3 Things You Should Know About the Multimodal Treatment of SCLC

Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
May 19th 2025
Article

Here are 3 things you should know about the multimodal treatment of patients with SCLC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.